In this Lung Cancer Awareness Month video, members of Oncology Data Advisor and MedNews Week join forces to share global perspectives regarding treatment, equity, and patient advocacy in lung cancer.
In this Lung Cancer Awareness Month video, members of Oncology Data Advisor and MedNews Week join forces to share global perspectives regarding treatment, equity, and patient advocacy in lung cancer.
The FDA has approved repotrectinib (Augtyro™, Bristol Myers Squibb Company) for locally advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC). This is the first approval for the next-generation ROS1/TRK tyrosine kinase inhibitor (TKI) repotrectinib and is the first FDA approval to include patients with ROS1-positive NSCLC who have previously received a ROS1 TKI, as well as patients who are TKI-naive. Why it matters: "Repotrectinib is a next-generation ROS1 and TRK TKI th...
Oncology Data Advisor® · Lung Cancer Awareness Month With Waqas Haque, Samuel Kareff, & Matthew Hadfield On the first day of Lung Cancer Awareness Month, members of Oncology Data Advisor's Fellows Forum joined forces to share recent research in lung cancer diagnosis and screening, the need to address disparities experienced by patients, and ways to raise awareness for patients, the public, and the health care community throughout the month of November. Hear unique perspectives fro...
At the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Janet Espirito, PharmD, a Senior Medical Director at Ontada, sat down with Oncology Data Advisor to discuss her presentation on identifying real-world end points for assessing response in patients receiving novel therapies for metastatic non–small cell lung cancer (NSCLC) outside of clinical trials.
Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Ticiana Leal, MD
Last year, Dr. Ticiana Leal, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, recorded a continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity titled Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer (NSCLC). With numerous developments in the field occurring since recording the activity, including new FDA approvals and clinical trial results, Dr. Leal sat down with Oncology Data Advisor to provide an update on the rapidly evolving field of NSCLC immunotherapy.
Additional Advances in Non–Small Cell Lung Cancer Research and Clinical Trials With Ticiana Leal, MD
Last year, Dr. Ticiana Leal, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, recorded a continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity titled Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer (NSCLC). With numerous developments in the field occurring since recording the activity, including new FDA approvals and clinical trial results, Dr. Leal sat down wit...
An educational activity offered by i3 Health has provided significant knowledge gains regarding strategies to enhance the clinical outcomes of patients with extensive-stage small cell lung cancer (SCLC) Among the 238,340 new cases of lung cancer reported in the United States each year, approximately 14% of cases are classified as small cell, a more aggressive subtype compared with its non–small cell counterpart. Most patients present with advanced or metastatic disease, making systemic therapy t...
Recently, Dr. Henry Park, Chief of Thoracic Radiotherapy at Smilow Cancer Network of Yale School of Medicine, served as faculty for i3 Health's CME/NCPD/CPE–approved activity, Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer (SCLC). This month, numerous updates in the use of radiotherapy for SCLC were presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting. In this interview, Dr. Park outlines the most significant updates presented at ASTRO and how he plans to incorporate them into the treatment of patients with SCLC.
On the first day of Lung Cancer Awareness Month, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined forces to share recent advances in lung cancer research and ways to raise awareness of this disease for both the public and the health care community throughout the month of November. Hear unique perspectives from Matthew Hadfield, DO, Hematology/Oncology Fellow at Brown University; Waqas Haque, MD, MPH, Internal Medicine Resident at New York University; and Samuel Kareff, MD, MPH, Hematology-Oncology Fellow at the University of Miami.
The FDA has approved a new indication for pafolacianine (Cytalux®, On Target Laboratories), a diagnostic agent, for the identification of lung cancer lesions in adult patients with known or suspected lung cancer who are undergoing surgery. Administered intravenously prior to surgery, pafolacianine is designed to locate additional hard-to-detect lung cancerous tissue. The safety and efficacy of pafolacianine were evaluated in the randomized, multicenter, open-label, phase 3 ELUCIDATE trial (NCT04...
Emphasizing Communication and Expectations for Lung Cancer Side Effects With Blanca Ledezma, MSN, NP
With the advent of targeted therapies in lung cancer, patients are experiencing improved outcomes through personalized medicine. However, education regarding potential toxicity is crucial. In this interview, Blanca Ledezma, MSN, NP, shares the importance of setting up expectations for the side effects of targeted therapies for lung cancer and emphasizing communication with the health care team throughout the course of treatment. Oncology Data Advisor: Welcome to Oncology Data Advisor. Tod...
Emphasizing Communication and Expectations for Lung Cancer Side Effects With Blanca Ledezma, MSN, NP
With the advent of targeted therapies in lung cancer, patients are experiencing improved outcomes through personalized medicine. However, education regarding potential toxicity is crucial. In this interview, Blanca Ledezma, MSN, NP, shares the importance of setting up expectations for the side effects of targeted therapies for lung cancer and emphasizing communication with the health care team throughout the course of treatment.
The FDA has granted approval of cemiplimab-rwlc (Libtayo®, Regeneron Pharmaceuticals, Inc.) in combination with platinum-based chemotherapy for treatment of advanced non–small cell lung cancer (aNSCLC) with no epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS proto-oncogene 1 (ROS1) aberrations, and no prior systemic treatment. Cemiplimab-rwlc is a fully human immune checkpoint inhibitor targeting the programmed cell death receptor-1 (PD-1). "Pembrolizumab and ate...
In this interview with Oncology Data Advisor, Blanca Ledezma, MSN, NP, elucidates the current landscape of therapeutically actionable biomarkers in lung cancer and the promising future of precision medicine in this field. In addition, she explains the clinical applications for lung cancer biomarkers in nursing practice, including unique toxicity management and patient education for novel therapies.
On August 1st, Oncology Data Advisor hosted a live panel discussion in honor of World Lung Cancer Day, featuring Beth Sandy, MSN, CRNP, and Corey Langer, MD, both of the University of Pennsylvania Abramson Cancer Center. Ms. Sandy and Dr. Langer discussed the improvements in survival that have occurred in recent years due to the development of novel therapies, groundbreaking developments in the fields of immunotherapy and targeted therapy, and exciting advances that lay on the horizon for patients with lung cancer in the coming years.
On August 1st, Oncology Data Advisor hosted a live panel discussion in honor of World Lung Cancer Day, featuring Beth Sandy, MSN, CRNP, and Corey Langer, MD, both of the University of Pennsylvania Abramson Cancer Center. Ms. Sandy and Dr. Langer discussed the improvements in survival that have occurred in recent years due to the development of novel therapies, groundbreaking developments in the fields of immunotherapy and targeted therapy, and exciting advances that lay on the horizon for patients with lung cancer in the coming years.
In this interview with Oncology Data Advisor, Blanca Ledezma, MSN, NP, elucidates the current landscape of therapeutically actionable biomarkers in lung cancer and the promising future of precision medicine in this field. In addition, she explains the clinical applications for lung cancer biomarkers in nursing practice, including unique toxicity management and patient education for novel therapies.
For patients with extensive-stage small cell lung cancer (SCLC), cytotoxic chemotherapy remains a mainstay of treatment. However, myelosuppressive hematologic adverse events such as anemia, neutropenia, and thrombocytopenia pose a significant challenge to care. In a study recently presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Jerome Goldschmidt, medical oncologist at Blue Ridge Cancer Care and the ...
The FDA has approved nivolumab (Opdivo®, Bristol-Myers Squibb) in combination with platinum doublet chemotherapy for the treatment of adult patients with early-stage, resectable non–small cell lung cancer (NSCLC). Nivolumab is a fully human programmed cell death ligand 1 (PD-L1)–targeted antibody, and its use is approved without regard for PD-L1 expression level. "In patients with nonmetastatic NSCLC, surgery has curative potential, but 30% to 80% who undergo resection experience recurrenc...